PointState Capital LP lessened its position in shares of Puma Biotechnology Inc (NYSE:PBYI) by 21.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 605,360 shares of the biopharmaceutical company’s stock after selling 165,640 shares during the quarter. PointState Capital LP owned about 1.64% of Puma Biotechnology worth $52,908,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PBYI. Wells Fargo & Company MN raised its stake in shares of Puma Biotechnology by 10.0% during the 1st quarter. Wells Fargo & Company MN now owns 24,151 shares of the biopharmaceutical company’s stock worth $899,000 after acquiring an additional 2,201 shares in the last quarter. Swiss National Bank raised its stake in shares of Puma Biotechnology by 2.1% during the 1st quarter. Swiss National Bank now owns 54,730 shares of the biopharmaceutical company’s stock worth $2,036,000 after acquiring an additional 1,100 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Puma Biotechnology during the 1st quarter worth approximately $257,000. American International Group Inc. raised its stake in shares of Puma Biotechnology by 19.2% during the 1st quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock worth $630,000 after acquiring an additional 2,733 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. bought a new position in shares of Puma Biotechnology during the 1st quarter worth approximately $603,000. Hedge funds and other institutional investors own 80.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Puma Biotechnology Inc (PBYI) Position Lowered by PointState Capital LP” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/06/puma-biotechnology-inc-pbyi-position-lowered-by-pointstate-capital-lp.html.

Several research analysts recently commented on the stock. Citigroup Inc. reiterated a “buy” rating and set a $156.00 price objective (up previously from $114.00) on shares of Puma Biotechnology in a research note on Thursday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Stifel Nicolaus restated a “buy” rating and set a $118.00 price target (up previously from $105.00) on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Credit Suisse Group AG restated an “outperform” rating and set a $136.00 price target on shares of Puma Biotechnology in a research note on Wednesday, September 27th. Finally, Leerink Swann restated an “outperform” rating and set a $125.00 price target on shares of Puma Biotechnology in a research note on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $122.89.

Puma Biotechnology Inc (NYSE PBYI) traded down 1.33% during trading on Friday, reaching $122.60. 339,997 shares of the company’s stock traded hands. Puma Biotechnology Inc has a one year low of $28.35 and a one year high of $127.02. The firm’s 50 day moving average price is $100.67 and its 200-day moving average price is $73.32. The stock’s market cap is $4.56 billion.

Puma Biotechnology (NYSE:PBYI) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.78). On average, equities analysts anticipate that Puma Biotechnology Inc will post ($8.62) earnings per share for the current fiscal year.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 13,175 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the sale, the insider now directly owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Richard Paul Bryce sold 1,998 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total transaction of $188,771.04. Following the sale, the senior vice president now owns 27,246 shares in the company, valued at $2,574,202.08. The disclosure for this sale can be found here. Insiders have sold a total of 45,173 shares of company stock worth $4,738,189 over the last 90 days. Insiders own 22.70% of the company’s stock.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.